Téléchargez le livre : RAS: Past, Present, and Future
eBook Téléchargement , DRM LCP 🛈 DRM Adobe 🛈 ebook sans DRM
Lecture en ligne (streaming)
128,71 €
Téléchargement immédiat
Dès validation de votre commande
Ajouter à ma liste d'envies
Image Louise Reader présentation

Louise Reader

Lisez ce titre sur l'application Louise Reader.

badge apple Application Louise Reader
badge Android Application Louise Reader
Description
Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers. - Overview of the history and development of efforts to pharmacologically inhibit RAS. - Discussion of the biochemistry and biology of different RAS mutant proteins and how this might be effectively leveraged in the development of anti-RAS therapies. - Up-to-date reviews of the cutting-edge approaches to develop new anti-RAS pharmacologics.
Pages
356 pages
Collection
n.c
Parution
2022-01-29
Marque
Academic Press
EAN papier
9780128244852
EAN PDF
9780128244869
Informations sur l'ebook
Nombre pages copiables
35
Nombre pages imprimables
35
Taille du fichier
20531 Ko
Ce livre est accessible aux handicaps Voir les informations sur l'accessibilité
Prix
128,71 €
EAN EPUB SANS DRM
9780128244869
Informations sur l'ebook
Ce livre est accessible aux handicaps Voir les informations sur l'accessibilité
Prix
128,71 €

Suggestions personnalisées